Paul G Ambrose, Pharm. D., FIDSA
Paul G. Ambrose, Pharm.D., F.I.D.S.A., is President of the Institute for Clinical Pharmacodynamics (ICPD), Latham, New York, and an Honorary Research Fellow in Infectious Diseases at the University of Oxford, Oxford, UK and Adjunct Associate Research Professor at the University at Buffalo, Buffalo, New York. Dr. Ambrose’s areas of scientific inquiry primarily involve anti-infective translational science, with the goal of improving patient care through the application of pharmacokinetic-pharmacodynamic (PK-PD) principles. Dr. Ambrose received his Pharm.D. from the University of the Pacific and completed a Post-Doctoral Fellowship in infectious diseases at Hartford Hospital.
Mark Noe, PhD
Mark Noe, Ph.D., is Vice President of the Groton Center of Chemistry Innovation, an interdisciplinary department comprised of structural biology, analytical chemistry, synthesis technology, experimental design and computational analysis supporting Worldwide Medicinal Chemistry. In addition to his scientific leadership, Dr. Noe leads a number of supporting teams within Pfizer Research and Development, including Academic and Industry Relations for the chemistry discipline. He serves on multiple external scientific advisory panels for both academia and the biotechnology industry. Dr. Noe received his Ph.D. in organic chemistry from Harvard University.
Karen Bush, PhD
Karen Bush, Ph.D., is a Fellow of the American Academy of Microbiology and a Professor of Practice in the biotechnology program in the Department of Molecular and Cellular Biology at Indiana University, where she is also an Adjunct Professor of Biology. She currently leads a small research group that evaluates new antibacterial agents and novel resistance mechanisms in carbapenem-resistant Enterobacteriaceae (CRE). Dr. Bush was involved with pharmaceutical research from 1973 to 2009, primarily working in the area of antibiotic drug discovery and development at Squibb (Bristol-Myers Squibb), Lederle (Wyeth), Astra and Johnson & Johnson Pharmaceutical Research & Development. She is especially known for her work on beta-lactamases. Dr. Bush was a member of research teams that served to discover and/or develop aztreonam, piperacillin-tazobactam, levofloxacin, doripenem and ceftobiprole. Dr. Bush received a Ph.D. in biochemistry from Indiana University.
Stanley A. Nasraway, Jr., MD, MCCM
Stanley A. Nasraway, Jr., M.D., M.C.C.M., is Professor of Surgery, Medicine, and Anesthesia at Tufts University School of Medicine and Director of the Surgical Intensive Care Units at the Tufts Medical Center in Boston. His interests are in sepsis and shock resuscitation, processes of care and outcomes research. In 2015, he completed a 2-center pilot study testing the utility of presepsin as a sepsis biomarker after enrolling 200 patients. He is a member of the Editorial Board for Critical Care Medicine, a master of the American College of Critical Care Medicine, and a fellow of the American College of Physicians and the American College of Chest Physicians. Dr. Nasraway received his M.D. from Keck School of Medicine of the University of Southern California.
Andrew F. Shorr, MD, MPH
Andrew F. Shorr, MD, MPH, is Director of Pulmonary and Critical Care at the Washington Hospital Center and Professor of Medicine at Georgetown University. He received his undergraduate degree (public policy) from Princeton University, an MPH from Johns Hopkins University, and his medical degree from the University of Virginia. He is currently completing his MBA studies at the Darden School of Business at the Univ. of Virginia. Dr Shorr’s research interests address healthcare outcomes, epidemiology in pulmonology/critical care, and infection in the hospitalized patient. He is specifically focused currently on issues related to anti-infective resistance, novel clinical trial designs, and the unmet need for new therapies. Dr Shorr is the author/co-author of nearly 300 peer-reviewed manuscripts and book chapters. He has served on the editorial board of Chest, currently serves on the editorial board of Critical Care Medicine, and is a reviewer on several medical and critical care journals. He also served as a Fullbright Specialist Scholar in Australia in 2010 and recently won the Sol Katz Award for Excellence in Teaching from the American College of Physicians.
Helen W. Boucher, MD, FACP, FIDSA
Helen W. Boucher, MD, FACP, FIDSA
Helen Boucher is Director of the Infectious Diseases Fellowship Program at Tufts Medical Center and Professor of Medicine at Tufts University School of Medicine. Dr. Boucher’s clinical interests include infections in immunocompromised patients and S. aureus infections. Her research interests focus on S. aureus and the development of new anti-infective agents. She is the author or coauthor of numerous abstracts, chapters and peer-reviewed articles, which have been published in such journals as The New England Journal of Medicine, Antimicrobial Agents and Chemotherapy, Clinical Infectious Diseases, and The Annals of Internal Medicine; she is Associate Editor of Antimicrobial Agents and Chemotherapy. She has been included in Best Doctors in America since 2009. In 2011, Dr. Boucher was elected Fellow and Member of the Board of Directors of the Infectious Diseases Society of America. In 2012, she was elected to the American Board of Internal Medicine Infectious Disease Exam Writing Committee and in 2014, to the American Board of Internal Medicine Infectious Diseases Subspecialty Board. In 2015 she was appointed to the Presidential Advisory Council on Combating Antibiotic-resistant Bacteria, and elected Treasurer of the Infectious Diseases Society of America. She was awarded the IDSA Society Citation Award in October, 2015. Dr. Boucher serves on the Board of Trustees of the Physicians of Tufts Medical Center and The College of the Holy Cross.